What is a stock summary page? Click here for an overview.
Business Description
Optimind Pharma Corp
NAICS : 325412
SIC : 3741
ISIN : CA68405U1012
Description
Optimind Pharma Corp is an emerging provider of psychedelic therapies for the masses. It helps people suffering from PTSD, Anxiety, Depression, and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities. It is also partnered with developers of psilocybin-associated treatments and products to further expand its treatment and program offerings.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.82 | |||||
| Equity-to-Asset | -0.23 | |||||
| Debt-to-Equity | -2.63 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -44.28 | |||||
| Beneish M-Score | -6.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 100 | |||||
| 9-Day RSI | 100 | |||||
| 14-Day RSI | 99.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.62 | |||||
| Quick Ratio | 0.62 | |||||
| Cash Ratio | 0.39 | |||||
| Days Sales Outstanding | 96.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 44.47 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -292.86 | |||||
| Net Margin % | -800 | |||||
| FCF Margin % | -178.57 | |||||
| ROA % | -260.77 | |||||
| ROIC % | -86.05 | |||||
| ROC (Joel Greenblatt) % | -1089.02 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
| PS Ratio | 10 | |||||
| EV-to-EBIT | -1.26 | |||||
| EV-to-EBITDA | -1.26 | |||||
| EV-to-Revenue | 10.01 | |||||
| EV-to-FCF | -5.61 | |||||
| Earnings Yield (Greenblatt) % | -79.37 | |||||
| FCF Yield % | -18.21 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Optimind Pharma Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 0.112 | ||
| EPS (TTM) (C$) | -0.005 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 162.37 | ||
| 14-Day RSI | 99.84 | ||
| 14-Day ATR (C$) | 0.000188 | ||
| 20-Day SMA (C$) | 0.0075 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (C$) | 0.005 - 0.01 | ||
| Shares Outstanding (Mil) | 109.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Optimind Pharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Optimind Pharma Corp Stock Events
| Event | Date | Price (C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Optimind Pharma Corp Frequently Asked Questions
What is Optimind Pharma Corp(XCNQ:OMND)'s stock price today?
The current price of XCNQ:OMND is C$0.01. The 52 week high of XCNQ:OMND is C$0.01 and 52 week low is C$0.01.
When is next earnings date of Optimind Pharma Corp(XCNQ:OMND)?
The next earnings date of Optimind Pharma Corp(XCNQ:OMND) is .
Does Optimind Pharma Corp(XCNQ:OMND) pay dividends? If so, how much?
Optimind Pharma Corp(XCNQ:OMND) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers